HOWL
What one share of Werewolf Therapeutics holds
Pharmaceutical Preparations
We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies.
Werewolf Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.71 |
|---|---|
| Cash and investments | $0.45 |
| Debt | $0.66 |
| Book value | $0.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$28.08 | $0.56 | −$19.09 | — | −$43.80 |
| 2021 | — | −$10.94 | $0.03 | −$2.35 | — | $5.59 |
| 2022 | — | −$1.86 | $0.13 | −$1.53 | — | $3.89 |
| 2023 | — | −$1.05 | $0.02 | −$0.94 | — | $2.85 |
| 2024 | — | −$1.63 | $0.01 | −$1.29 | — | $1.64 |
| 2025 | — | −$1.33 | $0.00 | −$1.29 | — | $0.51 |